| Clinical and genomic characterization of low–prostate-specific antigen, high-grade prostate cancer BA Mahal, DD Yang, NQ Wang, M Alshalalfa, E Davicioni, V Choeurng, ... European urology 74 (2), 146-154, 2018 | 97 | 2018 |
| Association of androgen deprivation therapy and depression in the treatment of prostate cancer: a systematic review and meta-analysis KT Nead, S Sinha, DD Yang, PL Nguyen Urologic Oncology: Seminars and Original Investigations 35 (11), 664. e1-664. e9, 2017 | 91 | 2017 |
| A population-based experimental model for protein evolution: effects of mutation rate and selection stringency on evolutionary outcomes AM Leconte, BC Dickinson, DD Yang, IA Chen, B Allen, DR Liu Biochemistry 52 (8), 1490-1499, 2013 | 58 | 2013 |
| Risk of upgrading and upstaging among 10 000 patients with Gleason 3+ 4 favorable intermediate-risk prostate cancer DD Yang, BA Mahal, V Muralidhar, MD Nezolosky, ME Vastola, SA Labe, ... European urology focus 5 (1), 69-76, 2019 | 52 | 2019 |
| Association between androgen deprivation therapy and anxiety among 78 000 patients with localized prostate cancer KT Dinh, DD Yang, KT Nead, G Reznor, QD Trinh, PL Nguyen International Journal of Urology 24 (10), 743-748, 2017 | 41 | 2017 |
| Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer S Alimena, DD Yang, A Melamed, BA Mahal, MJ Worley Jr, S Feldman, ... Gynecologic oncology 154 (3), 595-601, 2019 | 39 | 2019 |
| Combined external beam radiation therapy and brachytherapy versus radical prostatectomy with adjuvant radiation therapy for Gleason 9-10 prostate cancer V Muralidhar, BA Mahal, S Butler, N Lamba, DD Yang, J Leeman, ... The Journal of urology 202 (5), 973-978, 2019 | 28 | 2019 |
| Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer DD Yang, A Krasnova, KT Nead, TK Choueiri, JC Hu, KE Hoffman, JB Yu, ... Annals of Oncology 29 (2), 386-391, 2018 | 27 | 2018 |
| Early impact of the Affordable Care Act and Medicaid expansion on racial and socioeconomic disparities in cancer care AR Mahal, J Chavez, DD Yang, DW Kim, AP Cole, JC Hu, QD Trinh, ... American journal of clinical oncology 43 (3), 163-167, 2020 | 25 | 2020 |
| Androgen deprivation therapy and overall survival for Gleason 8 versus Gleason 9–10 prostate cancer DD Yang, BA Mahal, V Muralidhar, NE Martin, PF Orio, KW Mouw, ... European urology 75 (1), 35-41, 2019 | 25 | 2019 |
| Travel distance and stereotactic body radiotherapy for localized prostate cancer BA Mahal, YW Chen, RV Sethi, OA Padilla, DD Yang, J Chavez, ... Cancer 124 (6), 1141-1149, 2018 | 25 | 2018 |
| Laboratory eligibility criteria as potential barriers to participation by black men in prostate cancer clinical trials ME Vastola, DD Yang, V Muralidhar, BA Mahal, CS Lathan, BA McGregor, ... JAMA oncology 4 (3), 413-414, 2018 | 25 | 2018 |
| Receipt of definitive therapy in elderly patients with unfavorable‐risk prostate cancer DD Yang, BA Mahal, V Muralidhar, N Boldbaatar, SA Labe, ... Cancer 123 (24), 4832-4840, 2017 | 24 | 2017 |
| Association of androgen deprivation therapy and thromboembolic events: a systematic review and meta-analysis KT Nead, N Boldbaatar, DD Yang, S Sinha, PL Nguyen Urology 114, 155-162, 2018 | 22 | 2018 |
| Identifying the best candidates for prostate-specific membrane antigen positron emission tomography/computed tomography as the primary staging approach among men with high-risk … TM Ma, A Gafita, D Shabsovich, J Juarez, TR Grogan, P Thin, ... European urology oncology 5 (1), 100-103, 2022 | 21 | 2022 |
| A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer MT King, DD Yang, V Muralidhar, B Mahal, S Butler, PM Devlin, LJ Lee, ... Brachytherapy 18 (2), 186-191, 2019 | 20 | 2019 |
| Prostate cancer‐specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities EC Dee, MD Nezolosky, FE Chipidza, MA Arega, SS Butler, ST Sha, ... The Prostate 80 (13), 1128-1133, 2020 | 19 | 2020 |
| Local therapy outcomes and toxicity from the ATEMPT trial (TBCRC 033): a phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with … JR Bellon, N Tayob, DD Yang, J Tralins, CT Dang, SJ Isakoff, M DeMeo, ... International Journal of Radiation Oncology* Biology* Physics 113 (1), 117-124, 2022 | 17 | 2022 |
| Pathologic outcomes of gleason 6 favorable intermediate-risk prostate cancer treated with radical prostatectomy: implications for active surveillance DD Yang, BA Mahal, V Muralidhar, ME Vastola, N Boldbaatar, SA Labe, ... Clinical genitourinary cancer 16 (3), 226-234, 2018 | 17 | 2018 |
| Disparities in refusal of locoregional treatment for prostate adenocarcinoma EC Dee, MA Arega, DD Yang, SS Butler, BA Mahal, NN Sanford, ... JCO oncology practice 17 (10), e1489-e1501, 2021 | 15 | 2021 |
